Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients
Secondary pulmonary hypertension
Mean pulmonary artery pressure equal or above 40 mmHg or primary pulmonary hypertension with a pressure equal or above 30 mmHg while resting during appropriate conventional treatment
Written informed consent after having been duly informed about all diagnostic and therapeutic measures involved in the study
Myocardial infarction or major cardiac surgery within 3 months prior to baseline
Bleeding disorders or bleeding risk
Severe hepatic insufficiency or renal insufficiency
Malignant diseases
HIV positive
Pregnancy, female patients of child-bearing potential without adequate contraception and nursing mothers
Congenital or acquired valvular defects and myocardial function disorders not related to pulmonary hypertension
Prior pulmonary embolism
Collagenosis
Pulmonary arterial or valvular stenosis
Clareo Health | Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
